vs

Side-by-side financial comparison of Connect Biopharma Holdings Ltd (CNTB) and CuriosityStream Inc. (CURI). Click either name above to swap in a different company.

Connect Biopharma Holdings Ltd is the larger business by last-quarter revenue ($24.1M vs $19.2M, roughly 1.3× CuriosityStream Inc.). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs -19.7%, a 81.3% gap on every dollar of revenue.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

CNTB vs CURI — Head-to-Head

Bigger by revenue
CNTB
CNTB
1.3× larger
CNTB
$24.1M
$19.2M
CURI
Higher net margin
CNTB
CNTB
81.3% more per $
CNTB
61.6%
-19.7%
CURI

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CNTB
CNTB
CURI
CURI
Revenue
$24.1M
$19.2M
Net Profit
$14.8M
$-3.8M
Gross Margin
Operating Margin
56.6%
-17.6%
Net Margin
61.6%
-19.7%
Revenue YoY
35.8%
Net Profit YoY
148.7%
-34.6%
EPS (diluted)
$0.27
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNTB
CNTB
CURI
CURI
Q4 25
$19.2M
Q3 25
$18.4M
Q2 25
$19.0M
Q1 25
$15.1M
Q4 24
$14.1M
Q3 24
$12.6M
Q2 24
$24.1M
$12.4M
Q1 24
$12.0M
Net Profit
CNTB
CNTB
CURI
CURI
Q4 25
$-3.8M
Q3 25
$-3.7M
Q2 25
$784.0K
Q1 25
$319.0K
Q4 24
$-2.8M
Q3 24
$-3.1M
Q2 24
$14.8M
$-2.0M
Q1 24
$-5.0M
Operating Margin
CNTB
CNTB
CURI
CURI
Q4 25
-17.6%
Q3 25
-24.5%
Q2 25
2.5%
Q1 25
0.5%
Q4 24
-27.4%
Q3 24
-25.8%
Q2 24
56.6%
-20.6%
Q1 24
-30.4%
Net Margin
CNTB
CNTB
CURI
CURI
Q4 25
-19.7%
Q3 25
-20.4%
Q2 25
4.1%
Q1 25
2.1%
Q4 24
-19.9%
Q3 24
-24.3%
Q2 24
61.6%
-16.4%
Q1 24
-42.0%
EPS (diluted)
CNTB
CNTB
CURI
CURI
Q4 25
$-0.07
Q3 25
$-0.06
Q2 25
$0.01
Q1 25
$0.01
Q4 24
$-0.05
Q3 24
$-0.06
Q2 24
$0.27
$-0.04
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNTB
CNTB
CURI
CURI
Cash + ST InvestmentsLiquidity on hand
$110.2M
$27.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$110.9M
$41.5M
Total Assets
$120.6M
$75.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNTB
CNTB
CURI
CURI
Q4 25
$27.3M
Q3 25
$27.8M
Q2 25
$28.1M
Q1 25
$33.4M
Q4 24
$32.1M
Q3 24
$33.2M
Q2 24
$110.2M
$39.5M
Q1 24
$38.8M
Stockholders' Equity
CNTB
CNTB
CURI
CURI
Q4 25
$41.5M
Q3 25
$47.2M
Q2 25
$49.8M
Q1 25
$58.1M
Q4 24
$57.8M
Q3 24
$62.2M
Q2 24
$110.9M
$64.8M
Q1 24
$67.0M
Total Assets
CNTB
CNTB
CURI
CURI
Q4 25
$75.7M
Q3 25
$74.7M
Q2 25
$78.7M
Q1 25
$85.3M
Q4 24
$86.2M
Q3 24
$87.6M
Q2 24
$120.6M
$90.9M
Q1 24
$94.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNTB
CNTB
CURI
CURI
Operating Cash FlowLast quarter
$-8.0M
$4.0M
Free Cash FlowOCF − Capex
$3.9M
FCF MarginFCF / Revenue
20.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-0.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNTB
CNTB
CURI
CURI
Q4 25
$4.0M
Q3 25
$4.4M
Q2 25
$2.8M
Q1 25
$1.9M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$-8.0M
$2.2M
Q1 24
$666.0K
Free Cash Flow
CNTB
CNTB
CURI
CURI
Q4 25
$3.9M
Q3 25
Q2 25
Q1 25
$1.8M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
CNTB
CNTB
CURI
CURI
Q4 25
20.5%
Q3 25
Q2 25
Q1 25
12.2%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
CNTB
CNTB
CURI
CURI
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CNTB
CNTB
CURI
CURI
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
-0.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons